Bradley Merrill Thompson, Strategic Advisor with EBG Advisors and Member of the Firm in the Health Care & Life Sciences practice at Epstein Becker Green, was quoted in MarketPathways, in “Racial Equity Increasing in Device Trials, but Reporting Remains Low,” by Stephen Levin. (Read the full version – subscription required.)
Following is an excerpt:
Health equity is being recognized as an increasingly important issue across all aspects of our healthcare system. In addition to being significant in terms of fundamental fairness in matters such as employment, equity also has clinical implications resulting from the differing safety and efficacy impacts that therapeutic products and procedures can have on diverse racial and ethnic patient populations. Such determinations can only be made by ensuring that clinical trials encompass a real-world cross section of prospective patients. Bradley Merrill Thompson, a member of Epstein Becker Green’s life sciences practice specializing in regulatory law and digital health, including artificial intelligence (AI) and data science, took a look at the racial composition of device clinical trials for Market Pathways, based on information reported by product companies and publicly available at www.clinicaltrials.gov.
Related reading:
“Unpacking Averages: Assessing the Racial Composition of Drug Clinical Trial Subjects,” by Bradley Merrill Thompson, Health Law Advisor.
